Please login to the form below

Not currently logged in
Email:
Password:

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

FDA approves first drug to prevent graft-versus-host disease

FDA approves first drug to prevent graft-versus-host disease

received Orencia saw a 98% overall survival rate compared to 75% for patients who received standard immunosuppression alone. ... Israel”, said BMS, although it stressed that Orencia was not yet approved for this indication in those countries.

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • BMS’ Brian Daniels to retire BMS’ Brian Daniels to retire

    Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...